At the 2025 Tianqiao Brain Science Institute Brain-Computer Interface and Artificial Intelligence Forum, held on December 13, Shanghai NeuroXess Technology Co., Ltd. made a groundbreaking announcement. The company revealed that its independently developed 'Three-All' brain-computer interface (BCI) product—which stands for fully implantable, fully wireless, and fully functional—has successfully completed its inaugural clinical trial. This BCI device is the first of its kind in China and only the second globally to feature a built-in battery.

The clinical trial was overseen by a team led by Professor Mao Ying and Professor Chen Liang from Huashan Hospital, Fudan University. The subject of the trial was a patient who had been living with high-level paraplegia for eight years. Remarkably, just one day after the surgery, the patient was moved to a general ward. On the fifth day post-operation, during the initial activation phase, the patient successfully demonstrated mind control capabilities. After undergoing systematic training, the patient's brain-control decoding rate soared to 5.2 bits per second, a level that is on par with the international top tier.

This innovative product boasts the complete implantation of all core modules within the body, leaving no cable interfaces exposed on the surface. From a physical standpoint, this design eliminates the risk of infection associated with traditional exposed systems. Moreover, the device seamlessly integrates wireless power supply and wireless data transmission functions. This integration allows patients to fully break free from the constraints of external devices, granting them true 'wireless freedom' in terms of both mobility and dignity.

Additionally, the product exhibits remarkable openness and scalability. This characteristic paves the way for a novel approach to helping aphasia patients regain their language communication abilities in the future.